BOARD OF PHARMACY
Executive Officer: Virginia Herold ◆ (916) 574–7900 ◆ Internet:
http://www.pharmacy.ca.gov
Protection of the public shall be the highest priority for the California State
Board of Pharmacy in exercising its licensing, regulatory and disciplinary
functions. Whenever the protection of the public is inconsistent with other
interest sought to be promoted, the protection of the public shall be
paramount.
— Business and Professions Code § 4001.1

P

ursuant to Business and Professions Code section 4000 et seq., the

Board of Pharmacy grants licenses and permits to pharmacists,
pharmacy interns, pharmacy technicians, pharmacies, pharmacy

corporations, nonresident pharmacies, wholesale drug facilities, veterinary food-animal
drug retailers, out-of-state distributors, clinics, hypodermic needle and syringe distributors,
and an extensive array of associated individuals and entities. The Board regulates all sales
of dangerous drugs, controlled substances, and poisons, and is authorized to adopt
regulations, which are codified in Division 17, Title 16 of the California Code of
Regulations (CCR).
The Board of Pharmacy is a consumer protection agency located within the
Department of Consumer Affairs (DCA). It consists of 13 members, six of whom are public
members. The Governor appoints four public members and the Senate Committee on Rules
and the Speaker of the Assembly each appoint one. The remaining members are
pharmacists, appointed by the Governor, five of whom must be active practitioners.
Additionally, Business and Professions Code section 4001(c) requires that the membership
of the Board include at least one pharmacist representative from each of the following
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practice settings: an acute care hospital, an independent community pharmacy, a chain
community pharmacy, and a long-term health care or skilled nursing facility. Furthermore,
the Board must include a pharmacist who is a member of a labor union that represents
pharmacists. All Board members are appointed to four-year terms.
There were no appointments during this reporting period, and the Board currently
has no vacancies.

MAJOR PROJECTS
Inventory Reconciliation Report of Controlled
Substances
On January 25, 2018, the OAL approved the Board’s proposed adoption of new
section 1715.65, Title 16 of the CCR, which requires all pharmacies and clinics licensed
by the board to maintain quarterly inventory reconciliation reports of federal Schedule II
controlled substances in order to prevent the loss of such substances. [23:1 CRLR 76-77].
At its March 27, 2018 meeting, the Board directed staff to update its Frequently Asked
Questions (FAQ) relating to inventory reconciliation reports consistent with the newly
effective regulations. The regulation became effective on April 1, 2018.

Emergency Regulations Regarding Compounded
Drug Preparations
On December 1, 2017, the Board proposed emergency action to amend its
regulations related to the establishment of beyond use dates (BUDs) for compounded drug
preparations. Specifically, the Board proposes to amend section 1735.2, Title 16 of the
CCR, to allow for an extension of the BUDs of non-sterile compounded drug preparations,
and to clarify that suitability and integrity tests and stability studies are only required to
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extend the beyond use date of sterile compounded drug preparations. According to the
Board’s finding of emergency, the Board significantly amended its compounding
regulations, after three years of discussion and stakeholder input, on January 1, 2017.
Following implementation of the amended regulations, however, the Board heard concerns
from various stakeholders that some of the new requirements were having a significant
unintended impact on patients’ ability to receive their medications.
After holding two public committee meetings on this topic, and considering the
comments made therein, the Board, at its July 2017 meeting, found that there is a significant
adverse impact to patients related to the current requirements for establishing BUDs for
non-sterile compounded drug preparations. The Board further found that each day the
existing regulations are in place, there is a significant risk that patients will be deprived
access to needed medications. Because of the immediate need for relief from the Board’s
existing regulations that restrict patients’ access to drugs, the Board found it necessary, and
approved language, to adopt these changes on an emergency basis. OAL approved the
proposed emergency rulemaking on December 19, 2017. The emergency regulation will
expire on June 19, 2018.

OAL Approves Board’s Regulations to Update
Disciplinary Guidelines
On January 17, 2018, the Board approved the Board’s resubmitted rulemaking
proposal to amend its Manual of Disciplinary Guidelines and Model Disciplinary Orders,
which is incorporated by reference in section 1760, Title 16 of the CCR. OAL rejected the
Board’s original January 23, 2017 proposal, finding that the regulations failed to comply
with the consistency, clarity, and necessity standards of Government Code section 11349.1
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and that the Board failed to follow procedural requirements of the California
Administrative Procedure Act (APA). The Board revised the guidelines to address OAL’s
concerns, and approved the final text, after a 15-day public comment period, on March 30,
2017. The regulations became effective on April 1, 2018.

Board Submits Reports to the Legislature on
Regulation of Compounding Pharmacies
On January 1, 2018, the Board submitted two reports to the legislature pertaining
to its licensure and regulation of sterile compounding pharmacies. The reports are
mandated pursuant to SB 294 (Emmerson) (Chapter 565, Statutes of 2013), which adds
section 4127.2 to the Business and Professions Code to impose new licensure and
regulation requirements in California for both in-state and nonresident pharmacies
performing sterile compounding and doing business in California. The legislature imposed
the new licensing scheme in response to a national public health emergency originating in
a Massachusetts pharmacy in 2012 that resulted in serious health consequences to patients
across the United States. Specifically, statute required an increase in the frequency and
quality of the Board’s inspections of these pharmacies, including annual inspections of all
sterile compounding pharmacies in California, and out-of-state pharmacies that ship sterile
preparations into California.
Pursuant to section 4127.2(g), the Board submitted a Report to the Legislature on
Inspections of Nonresident Sterile Compounding Pharmacies, detailing its activities and
efforts to inspect sterile compounded preparations where out-of-state facilities prepared the
medication.
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Relatedly, SB 1193 (Hill) (Chapter 484, Statutes of 2016) adds section 4129.3 of
the Business and Professions Code, which establishes the Board’s licensure and regulation
duties over facilities outside of California, licensed with the FDA as outsourcing facilities
that perform sterile and other compounding services in or into California. The Board’s first
outsourcing facility licenses were issued in June 2017. Pursuant to section 4129.3(a), the
Board issued its Report to the Legislature on Inspections of Nonresident Outsourcing
Facilities, detailing the Board’s efforts to inspect and regulate these facilities.
While Board staff provided the draft reports to the legislature in compliance with
the January 1, 2018 deadline, the Board voted to approve the reports at its January 11, 2018
meeting. The Board-approved reports were submitted on January 18, 2018.

Board Votes to Create Webinar Course for
Naloxone Certification
At the Board’s February meeting, the Communication and Public Education
Committee chair, Board member Deborah Veale, recommended to the Board that it
approve a webinar course to satisfy the education requirements for pharmacists to furnish
naloxone, a drug which reverses opioid overdose. This is a follow up to SB 493
(Hernandez) (Chapter 469, Statutes of 2013), which authorizes the Board to address the
problem of restricted public access to naloxone. In 2016, the Board adopted a regulation
establishing a protocol for pharmacists to furnish naloxone to individuals (usually family
and friends of drug users) without a prescription. Executive Officer, Virginia Herold,
reported that the Board had certified 700 pharmacists to provide naloxone by attending an
in-person training provided by the Board and DEA. The goal of this webinar is to expand
the training and certification process for additional pharmacists, particularly those in rural
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areas. The Board unanimously voted to proceed with the webinar at the committee’s
recommendation.

LEGISLATION
Combatting the Opioid Crisis
In February of 2018, a bipartisan coalition of California State Assembly members
announced a package of legislation aimed at combating the opioid crisis; which was
declared a national emergency by the President in October 2017. The bills represent a
diversity of approaches to curbing overprescription, encouraging treatment, and preventing
diversion of dangerous drugs. Those bills impacting the Board of Pharmacy include:
AB 2783 (O’Donnell), as amended April 11, 2018, would amend sections 11055
and 11056 of the Business and Professions Code to reclassify hydrocodone combination
products (HCPs) on California’s controlled Substances Schedules from Schedule III to
Schedule II controlled substances. According to the author, this change would conform
California’s schedule to the Federal schedule, which reclassified HCPs as Schedule II drugs
in 2014. In a statement supporting the bill, the Board stated, “The reclassification of these
drugs in California will aid practitioners in being compliant with the conditions for
prescribing and refilling Schedule II medications, which are the most highly regulated tier
of prescription medication.” [A. PubSafe]
AB 2859 (Caballero), as amended April 12, 2018, entitled the Protecting our
Children and Adolescents from Opioids Act of 2018, would add and repeal section 4106.5
of the Business and Professions Code to require community pharmacies that dispense
Schedule II, III, or IV controlled substances to display safe storage products for sale within
the pharmacy department. The bill would define “safe storage products” to include a box,
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bag, or medicine cabinet with a locking device, or a medicine locking closure container
accessible only by the designated patient with a secure mechanism such as a prescription
container combined with a resettable alphanumeric code. The bill would also require the
Board to assess a fine for a violation of this requirement and would allow the Board to
choose not to take administrative action against the pharmacy if it determines that
compliance would create financial hardship on the pharmacy. According to the author,
patient safety advocates have championed the use of safe storage products designed to
access dangerous medications kept within the home, citing a report that found the number
of emergency room visits for accidental poisonings among toddlers has tripled since 1997.
The Assembly Appropriations Committee analysis noted that the bill would
establish a precedent by requiring retail pharmacies to display and sell at least one type of
commercial product that meets its specifications, and a sunset date of January 1, 2023 was
added to the bill “to allow for an assessment of whether this requirement results in safety
improvements that justify this type of state intervention into retail practices.” [A. Appr]
AB 1752 (Low), as amended April 5, 2018, is a Board-sponsored bill that would
amend sections 11165 and 11165.1 of the Health and Safety Code to add Schedule V drugs
to the Controlled Substance Utilization Review and Evaluation System (CURES) database.
The bill would also change the required timeframe in which pharmacists are required to
report dispensed prescriptions from seven days to the following business day. According
to the author, this would allow CURES to track frequently stolen or abused drugs, like
cough syrups containing opioids, addressing a serious deficiency in the database. In a
statement supporting its sponsorship of the bill, the Board stated that it “strongly advocates
for the enactment of these previsions (sic) for the benefits they will bring to the monitoring
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and dispensing of controlled substances to California patients …. Schedule V drugs are
highly abused medications, especially when coupled with other controlled drugs.” [A.
PubSafe]
AB 1753 (Low), as introduced January 3, 2018, would amend sections 11161.5,
11162.1, and 11165 of the Health and Safety Code to impose tighter security measures
involving the use of prescription pads to prescribe controlled substances. Specifically, the
bill would limit the number of security printers approved by the California Department of
Justice (DOJ) to manufacture regulated prescription pads to three, require that all
prescriptions be uniquely serialized, and require that the DOJ link prescription pad serial
numbers to corresponding records in CURES database, beginning January 1, 2020. The
bill would include a legislative finding that the use of paper prescription pads to prescribe
controlled substances leads to significant instances of theft and fraud each year; that
electronic prescribing is the most effective way to combat prescription pad theft and fraud;
and that tighter restrictions on prescription pads is needed for prescriptions not made
electronically. [A. PubSafe]
AB 2789 (Wood), as amended April 3, 2018, as is it pertains to the Board of
Pharmacy, would add section 688 to the Business and Professions Code to, on or after
January 1, 2020, require a pharmacy or pharmacist to have the capability to receive an eprescription. According to the author, an increase in the number and complexity of
prescriptions, the risk of errors, fraudulent prescriptions, and the diversion of prescribed
controlled substances to street use may be combatted by requiring e-prescribing. This bill
would mandate e-prescribing for prescribers and drug dispensers, by requiring prescribers
to have the capability to issue prescriptions electronically and dispensers to have the ability
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to receive such prescriptions, and would require a prescription to be issued as an electronic
data transmission, as of January 1, 2021. [A. Appr]
AB 2256 (Santiago), as introduced February 13, 2018, would add section 4119.9
to the Business and Professions Code to authorize a pharmacy or wholesaler to furnish
naloxone hydrochloride or other “opioid antagonists” (collectively, “naloxone”) to law
enforcement agencies under the following specified conditions: 1) the naloxone is
furnished exclusively for use by employees of the law enforcement agency who have
completed training; and 2) records regarding the acquisition of the naloxone are maintained
by the law enforcement agency for a period of three years. According to the Centers for
Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose
in 2016, representing a 28 percent increase over the previous year. [A. PubSafe]
AB 1751 (Low), as introduced January 3, 2018, would amend section 11165 of the
Health and Safety Code to provide a framework for CURES to connect with other states
that comply with California’s patient privacy and data security standards. Specifically, the
bill would authorize the California DOJ to enter into an agreement with an entity operating
an interstate data share hub to share prescription information with other states’ prescription
drug monitoring programs (PDMP), and would require that any agreement DOJ enters into
for interstate data sharing must ensure that access to data within CURES meets the same
patient privacy and data security standards required for direct access of CURES in
California. According to the author, the growing opioid crisis was the impetus for the bill,
and “[u]pgrading CURES to allow the DOJ to enter into interstate data sharing agreements
will provide invaluable cross-jurisdictional informational information to health
professionals seeking to make informed decisions on behalf of their patients, particularly
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those practicing in communities neighboring other states.” At its February 2018 meeting,
the Board voted to support the bill. In addition, the Board’s Executive Officer, Virginia
Herold, submitted a letter in support, noting that the bill would provide “more complete
information for California’s health care providers when prescribing or dispensing
controlled substances.” She also noted that sharing information between states would
capture prescriptions dispensed through mail order pharmacies, “which sometimes are
located outside California” and represent “24 percent of the $650 billion in manufacturers’
sales of prescription drugs in 2016.” [A. PubSafe]
Several Senate Bills additionally address the opioid crisis, including the following
which impact the Board:
SB 1109 (Bates), as amended April 4, 2018, as it relates to the Board, would add
section 4079 to the Business and Professions Code to require the Board to adopt an
emergency regulation that requires a warning label on all Schedule II controlled substance
vials or prescription bottles that addresses the risks of addiction and overdose when using
opioids. Senator Bates introduced this bill, sponsored by the San Diego District Attorney’s
office, in light of the U.S. opioid epidemic and the President’s declaration of the opioid
crisis a national public health emergency in October 2017, in efforts to curb the risk of
opioid addition in California. [S. BP&ED]
SB 1240 (Stone), as amended April 9, 2018, would amend section 4040 of, and add
section 4122.5 to, the Business and Professions Code, and amend section 11165 of the
Health and Safety Code, to expand the drugs required to be reported and monitored in the
CURES. Specifically, the bill would require all dangerous drugs and Schedule V controlled
substances to be reported, as well as a description of the diagnosis, condition, or purpose
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for which the prescription was issued and the directions for use to the list of information
pharmacies are required to report to CURES for each prescription. [S. BP&ED]
SB 1447 (Hernandez), as introduced on February 16, 2018, is a Board-sponsored
bill that would amend sections 4008 and 4400 of, add section 4017.3 to, Article 25
(commencing with section 4427) to, and repeal section 4105.5 of, the Business and
Professions Code to revise requirements for the operation and licensing of automated drug
delivery systems (ADDS). An ADDS is a machine that dispenses prescription drugs outside
of a pharmacy, and they enable healthcare settings to have access to limited pharmacy
services without bearing the cost and responsibility of having a full pharmacy. This bill is
the result of an 18-month study commissioned by the Board at Sharp Memorial Hospital
in San Diego, in which the study placed an ADDS in the hospital for the employees’ use.
The study concluded that ADDS was a convenient and safe extension of the hospital’s
pharmacy; that patients were satisfied with pharmacist access; and there were no
complaints from patients or pharmacists. This bill would create an ADDS licensing
program, provide definitions for types of ADDSs, consolidate provisions in various code
sections to improve clarity and accountability, and expand the settings in which an ADDS
device may be utilized. This bill would add to section 4008 to allow pharmacy inspectors
to enter locations of an ADDS to inspect the system. This bill would also amend section
4400 to set the fee for the license and auto-renewal of the license for an ADDS at $200,
with authorization to increase it to $250. The Board held a lengthy discussion about this
program, and voted to sponsor the legislation at its November 2017 meeting. [S. BP&ED]
AB 2037 (Bonta), as introduced February 6, 2018, would add section 4119.11 to
the Business and Professions Code to authorize a pharmacy to provide services through an
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ADDS to patients participating in federal drug discount programs and would establish
minimum safety and security standards that must be met by pharmacies that utilize this
program. Specifically, the bill would require pharmacies who use this program to obtain a
license from the Board to operate the ADDS; impose various rules regarding safety,
inventory control and security, tracking, dispensing, and record-keeping; and require the
ADDS used at the clinic to provide for patient consultation with a pharmacist via a
telecommunications link that has two-way audio and video. The bill is sponsored by a
imgRx, a Texas company that sells ADDS products. [A. Appr]
SB 1264 (Stone), as amended April 12, 2018, would amend section 14132.968 of
the Welfare and Institutions Code to require Medi-Cal to provide coverage for hypertension
medication management services provided by a pharmacist or an Advanced Practice
Pharmacists, pursuant to specified provisions of their scope of practice. According to the
author, “[e]ngaging pharmacists in the management of hypertension is crucial to achieving
goals for [] patients [who have been unable to control their hypertension]. Pharmacists are
highly effective at managing medications for hypertension and ensuring patients reach
blood pressure goals.” [S. BP&ED]
AB 2576 (Aguiar-Curry), as introduced February 15, 2018, as it applies to the
Board, would add section 4062.5 to the Business and Professions Codes, section 8628.5 to
the Government Code, and section 14132.723 to the Welfare and Institutions Code
regarding community clinic licensure during emergencies. This bill would require the
Board of Pharmacy to issue a temporary pharmacy or clinic permit to a requesting
pharmacy or clinic during a proclaimed state of emergency. The bill would authorize the
Governor to direct all state agencies to take actions designed to allow community clinics
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and health centers to provide services and receive reimbursement during or immediately
following the emergency. The bill further specifies that patients need not be physically
present on the premises of a community clinic in order for the Medi-Cal program to provide
reimbursement. [A. B&P]
AB 2863 (Nazarian), as amended April 11, 2018, would add section 1367.47 to
the Health and Safety Code, and section 10123.65 to the Insurance Code, relating to health
care coverage for prescription medications. Specifically, this bill would prohibit a health
plan, health insurer, or pharmacy benefit manager (PBM) from requiring patients to pay
the applicable co-pay amount of prescription medication if that amount is greater than the
retail price of the medication. According to the author, the copayment of an insured patient
suggests that the patient and insurer are sharing the total cost of the drug, in which the
patient pays the copayment, and the insurer pays the remaining cost. However,
investigations show that on some prescription claims, the total cost of the drug is less than
the patient’s copayment, and the insurer or PBM keeps the difference as a “clawback.” The
author further stated that pharmacists have expressed frustration that they are bound by
“gag clauses” in their contracts with PBMs not to disclose to patients when they could save
money by not using their insurance in such transactions. [A. Health]
SB 1442 (Wiener), as amended April 2, 2018, would add section 4113.5 to the
Business and Professions Code to prohibit a pharmacy from requiring a pharmacist
employee to engage in the practice of pharmacy unless the pharmacist is assisted at all
times by either another employee of the pharmacy or, if the pharmacy is located within
another establishment, an employee of the establishment within which the pharmacy is
located. Any knowing violation of this provision would be a crime, and would prevent the
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pharmacy from operating. The bill would also make a series of legislative findings,
including that pharmacists are often left alone for indeterminate periods of time in the
pharmacy and are, simultaneously, required to perform non-pharmacist functions such as
staffing cash registers and assisting consumers. The findings would further state that such
staffing inadequacies interfere with the professional responsibilities of licensed
pharmacists and pose a risk to the public health. [S. Appr]
SB 1254 (Stone), as amended April 2, 2018, would add section 4118.5 to the
Business and Professions Code, to require a pharmacist at a hospital pharmacy to obtain an
accurate medication profile or list for each high-risk patient upon admission and discharge
of the patient, and would authorize an intern pharmacist or a pharmacy technician to
perform this task if certain conditions are satisfied. According to the author, currently,
medication lists are obtained by a variety of individuals with varying knowledge about
medications, and there is no current requirement specifying what a hospital pharmacy must
obtain when high-risk patients are admitted and discharged regarding their medication
profile. The author cites the current lack of defined responsibility to ensure medication lists
are accurately obtained at hospital admission and discharge places patients at significant
risk for harm and readmissions. [S. BP&ED]
AB 2138 (Chiu, Low), as amended April 2, 2018, would amend various sections
of the Business and Professions Code relating to professional licensure applicants with
criminal records. Of note, the bill would limit the circumstances under which DCA boards
may deny professional licensure to individuals who have previously been convicted of
crimes; require DCA boards to develop criteria for determining whether a crime is directly
and adversely related to the qualifications, functions, or duties of the business or profession
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a board regulates; develop procedures when requesting or taking disciplinary action based
on an applicant’s criminal history; and require boards to annually report specified deidentified information relating to Board action pertaining to applicants with criminal
convictions, including the number of licensees who were affected, whether they provided
evidence of rehabilitation or mitigation; whether they appealed; the final disposition; and
the voluntarily provided information on race or gender of any applicant.
The bill is sponsored by a coalition of criminal justice advocacy groups who note
that California has among the highest recidivism rates in the nation, and one of the root
causes of high recidivism is the inability of prior offenders to secure gainful employment
upon reentry. According to the authors, “[a]ll too often, qualified people are denied
occupational licenses or have licenses revoked or suspended on the basis of prior arrests or
convictions, many of which are old, unrelated to the job, or have been judicially dismissed.
Alleviating barriers to occupational licensing is just one way California can reduce
recidivism and provide economic opportunity to all its residents.” [A. B&P]
SB 1021 (Wiener), as introduced February 7, 2018, would amend and repeal
section 1342.71 of the Health and Safety Code, and amend and repeal section 10123.193
of the Insurance Code, relating to prescription drug coverage. This bill would make
permanent several consumer protection measures imposed by AB 339 (Gordon) (Chapter
619, Statutes of 2015). Prior to that bill, insurance companies would routinely shift drug
costs onto consumers by placing high-cost specialty drugs on the upper tiers of their drug
formularies, which meant higher cost-sharing for consumers. Californians with serious and
chronic conditions like cancer, HIV/AIDS, multiple sclerosis, and lupus were particularly
vulnerable to higher out-of-pocket costs. Consumers often reached their out-of-pocket limit
90
California Regulatory Law Reporter ♦ Volume 23, No. 2 (Spring 2018) ♦
Covers October 16, 2017–April 15, 2018

of as much as $6,000 in the first month of the plan year when filling just one prescription.
AB 339 capped co-pays for a 30-day supply of a prescription drug at $250. This bill would
continue the copay cap of $250 for prescription drugs by mandating that health plan
contracts and health insurance policies cover a single-table drug regimen for the prevention
of HIV infection and AIDS, and end the January 1, 2020 sunset law that caps cost sharing
for a covered outpatient prescription, as well as other formulary requirements. Similarly to
the currently proposed AB 2863 (Nazarian), this bill would also codify a regulation that
prohibits a beneficiary from being charged more than the retail price for a prescription drug
when the applicable copayment or coinsurance is a higher amount. [A. Health]
AB 710 (Wood), as amended April 2, 2018, would add section 26002 to the
Business and Professions Code, and add section 11150.2 to the Health and Safety Code, to
amend the Medicinal and Adult-Use Cannabis Regulation and Safety Act to exclude
federally sanctioned cannabidiol (CBD) products from regulation, and authorize healing
arts licensees to prescribe such products. The two year bill proposes to make legislative
findings and declarations that both children and adults with epilepsy are in need of new
treatment options and that CBD has shown potential as an effective treatment option.
Pertinent to the Board, it would also declare that, upon a change in federal law permitting
the prescription, furnishing or dispensing of a CBD product, a pharmacist acting within her
scope of practice who dispenses a CBD product in accordance with federal law shall be
deemed to be in compliance with state law. [A. Rules]
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LITIGATION
On December 8, 2017, the San Diego Superior Court entered a stipulated final
judgment in the matter of People v. Target Corp., Case No. 37-2017-00045228-CU-BTCTL. The District Attorney Offices of San Diego, Riverside, and Alameda Counties filed
the complaint for injunction and other equitable relief for violation of California’s Unfair
Competition Law statutes on November 28, 2017, alleging that various Target Corporation
pharmacists failed to provide oral consultation to patients as required by section 1707.2,
Title 16 of the CCR. Under the terms of the stipulated judgment, Target pharmacists are
enjoined to comply with the consultation regulation, and Target Corp. was assessed
$90,000 in civil penalties ($30,000 to each of the three District Attorney’s offices), as well
as $5,000 to the Board of Pharmacy, $2,500 to the Consumer Protection Prosecution Trust
Fund, and $11,250 to each of the three District Attorney’s offices for reimbursement of the
costs of investigation.
This is the fourth such settlement pursued under the state’s unfair business practices
statutes, involving Target pharmacies.

RECENT MEETINGS
At its November 8-9, 2017 meeting, the Board voted to extend their UCSD ADDS
study to July 2019. The study at the University of California, San Diego, gathers data on
patient access to medication from ADDS. An extension of the study would provide
additional data and time for the Board to consider a regulation modification involving
ADDS to provide medication to patients.
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At its February 6-7, 2018 meeting, the Board considered and expressed support for
a series of public outreach campaigns regarding drug overdose prevention, including a
potential webinar and training on naloxone and corresponding responsibility; a public
service billboard message regarding drug abuse; materials to educate consumers and
pharmacists about the importance of having a patient medication history on hand when
being admitted to a hospital; and drug take-back collection programs.
Also at the February meeting, the Board discussed a recent U.C. Berkeley study,
published in the Journal of the American Medical Association in December 2017, that
reported only 11 percent of California pharmacies are dispensing hormonal contraception
to women without a prescription. SB 493 (Hernandez) (Chapter 469, Statutes of 2013),
authorizes California pharmacies to dispense hormonal contraception without a
prescription, and the Board adopted regulations establishing a protocol for pharmacists to
furnish self-administered hormonal contraception without a prescription in April 2016. The
study was based on a survey of pharmacies between February and April of 2017. The study
identifies several barriers to implementing the contraception portion of SB 493, including
pharmacists’ concerns about training, liability, staffing, and lack of reimbursement. The
Board discussed the report, but at this writing has not taken any action.
The Board discussed the proposed creation of an Advanced Hospital Pharmacy
Technician (AHT) Licensing Program. The Licensing Committee recommended a motion
to approve the draft language outlining duties, licensing requirements, and definitions. The
Board also discussed pharmacy technicians working at remote dispensing site pharmacies
(RDSP). Because pharmacy technicians can receive dangerous drugs and devices, and
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controlled substances, the Committee recommended a motion to direct staff to develop
regulation language for a pharmacy technician working in a RDSP.
At its March 27, 2018 meeting, the Board discussed its efforts to implement SB 752
(Stone) (Chapter 598, Statutes of 2017). That bill requires the Board to issue a license to
individuals who qualify for a designated representative—reverse distributor license. [23:1
CRLR 81]. Board president, Amy Gutierrez, reported that the application for this license
was made available on the Board’s website on March 1, 2018. The bill additionally requires
applicants to complete a Board-approved training program, and the Board voted, at staff’s
recommendation, to approve the program content proposed by SkillsPlus Inc. for a period
of five years, upon confirmation by a supervising inspector that the program correctly
covers applicable code sections. The Board also voted to require SkillsPlus to submit
annual updates regarding the content of the training plan to be reviewed by a supervising
inspector.
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